RxDoctor Payments Data

Faizul Haque, MD

Cardiovascular Disease · Walnut Creek, CANPI 1609952597

Payments from drug & device makers

$61,005in general payments, 2019–2025

Across 324 payments — averaging $188.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$40K
  • Abbott$16K
  • E.r. Squibb & Sons, L.L.C.$446
  • AstraZeneca$394
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$381
  • Novartis$318
  • plus $4K from 33 others

What the payments were for

  • Consulting fees$12,60058%
  • Travel & lodging$1,5897%
  • Food & beverage$7,59635%
  • Education$990%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$61,005 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$581,094
Medicare patients
1,784
Services billed
7,735

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban388$514,865
XareltoRivaroxaban83$110,140
Repatha SureclickEvolocumab74$77,141
MultaqDronedarone Hcl39$72,448
FarxigaDapagliflozin Propanediol69$64,502
JardianceEmpagliflozin38$43,657
BrilintaTicagrelor67$41,891
EntrestoSacubitril/Valsartan16$28,316
Praluent PenAlirocumab30$23,408
Rosuvastatin Calcium385$6,501
Ranolazine ErRanolazine39$4,351
Metoprolol Succinate304$4,256
Atorvastatin Calcium370$3,766
Ezetimibe78$3,526
Flecainide Acetate64$3,331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$514,865388 claims
Johnson & JohnsonXarelto$212$110,14083 claims
AstraZenecaFarxiga, Brilinta$394$106,393136 claims
Boehringer IngelheimJardiance$228$43,65738 claims
NovartisEntresto$318$28,31616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Walnut Creek

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →